本帖最后由 StephenW 于 2012-4-5 00:49 编辑
This is the list of presentations by BMS only. Others will be published to-morrow.
The complete list of Bristol-Myers Squibb data presentations is below. Abstracts can be accessed on the ILC/EASL website at http://www.easl.eu/_the-internat ... general-information
Title Date/Time
-------------------------------------------------------------------- -----------------
Chronic Hepatitis B: BARACLUDE (entecavir) Clinical Data
--------------------------------------------------------------------
Safety and Efficacy of Entecavir in Patients Receiving Liver April 19, 12:00 -
Transplant Due to Chronic Hepatitis B 1:30 p.m.
-------------------------------------------------------------------- -----------------
The ENTEBE Study: Safety and Efficacy of Entecavir Plus Tenofovir in April 19, 12:00 -
Adults with Chronic Hepatitis B and Previous Nucleos(t)ide Treatment 1:30 p.m.
Failure
-------------------------------------------------------------------- -----------------
Chronic Hepatitis B: Outcomes Research / Real-World Data
--------------------------------------------------------------------
Real-world Data on Treatment Modification from a Long-term April 19, 12:00 -
Observational Study of Chronic Hepatitis B Patients from 5 European 1:30 p.m.
Countries
-------------------------------------------------------------------- -----------------
Hepatitis C: Direct-Acting Antiviral Data
--------------------------------------------------------------------
Confirmation That Quadruple Therapy with Daclatasvir (NS5A April 19, 12:00 -
Inhibitor), Asunaprevir (NS3 Inhibitor) and Peginterferon/Ribavirin 1:30 p.m.
Results in High Rate of SVR4 in HCV Genotype 1 Null Responders
-------------------------------------------------------------------- -----------------
Potent Viral Suppression with All-Oral Combination of Daclatasvir April 19, 12:00 -
(NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-Ribavirin, in 1:30 p.m.
Treatment-Naive Patients with Chronic HCV GT1, 2, or 3
-------------------------------------------------------------------- -----------------
Dual Oral Therapy With The NS5A Inhibitor Daclatasvir (BMS-790052) April 19, 4:00 -
and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 6:00 p.m.
1b-Infected Null Responders or Ineligible/Intolerant to
Peginterferon/Ribavirin
-------------------------------------------------------------------- -----------------
A Description Of Virologic Escape In HCV Genotype 1-Infected April 21, 12:30 -
Patients Treated with Daclatasvir (BMS-790052) In Combination With 1:30 p.m.
Ribavirin and Peginterferon Alfa-2a or Peginterferon Alfa-2b
-------------------------------------------------------------------- -----------------
Triple Therapy with Daclatasvir (DCV; BMS-790052), Peginterferon April 21, 12:30 -
Alfa-2a and Ribavirin in HCV-Infected Prior Null and Partial 1:30 p.m.
Responders: 12-Week Results of Phase 2b COMMAND-2 Trial
-------------------------------------------------------------------- -----------------
A Phase 2a Study of BMS-791325, an NS5B Polymerase Inhibitor, with April 21, 12:30 -
Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients with 1:30 p.m.
Genotype 1 Chronic Hepatitis C Infection
-------------------------------------------------------------------- -----------------
Characterization of Viral Escape in HCV Genotype 1-Infected Patients April 21, 12:30 -
Treated with BMS-791325 and Pegulated Interferon-Alfa and Ribavirin 1:30 p.m.
-------------------------------------------------------------------- -----------------
Asunaprevir (ASV; BMS-650032), an NS3 Protease Inhibitor, in April 21, 12:30 -
Combination with Peginterferon and Ribavirin in Treatment-Naive 1:30 p.m.
Patients With Genotype 1 Chronic Hepatitis C Infection
-------------------------------------------------------------------- -----------------
Hepatitis C: PEG-Interferon Lambda Data
--------------------------------------------------------------------
Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a April 19, 4:00 -
(Alfa) in Treatment-Naive Patients with HCV Genotypes (G) 2 or 3: 6:00 p.m.
First SVR24 Results From EMERGE Phase IIb
-------------------------------------------------------------------- -----------------
Effect of Pegylated Interferon Lambda-1a on Low Densiy Lipoprotein April 21, 12:30 -
and Its Association with Virologic Response in Chronic Hepatitis C 1:30 p.m.
Patients in A Phase 2b Study
-------------------------------------------------------------------- -----------------
Exposure-Response Analyses of Pegylated Interferon Lambda (Lambda, April 21, 12:30 -
BMS-914143) in Patients with Chronic HCV Infection: Dose Selection 1:30 p.m.
For Phase 3 Clinical Trials
-------------------------------------------------------------------- -----------------
Hepatitis C: Outcomes Research / Real-World Data
--------------------------------------------------------------------
The Effect of Hepatitis C Treatment on Health-Related Quality of April 21, 12:30 -
Life, Work Productivity, and Healthcare Resource Use Among Patients 1:30 p.m.
in Europe
-------------------------------------------------------------------- -----------------
Development and Validation of Prediction Models For Risk of April 20, 12:30 -
Hepatocellular Carcinoma Among Hepatitis C Virus Infected Patients 2:00 p.m.
-------------------------------------------------------------------- -----------------
Evaluating Optimal Treatment Outcomes of Antiviral Therapy in April 20, 12:30 -
Hepatitis C For Prior Null Responders in the Era of First Generation 2:00 p.m.
Protease Inhibitors
-------------------------------------------------------------------- -----------------
Hepatocellular Carcinoma: Brivanib Data
--------------------------------------------------------------------
Brivanib Versus Placebo In Patients With Advanced Hepatocellular April 21, 3:30 -
Carcinoma (HCC) Who Failed or Were Intolerant to Sorafenib: Results 5:30 p.m.
From The Phase 3 Brisk-PS Study
-------------------------------------------------------------------- -----------------
Hepatocellular Carcinoma: Outcomes Research
--------------------------------------------------------------------
Observations of Hepatocellular Carcinoma (HCC) Management Patterns April 20, 12:30 -
from the Global HCC BRIDGE Study: Second Interim Analysis of the 2:00 p.m.
European (EU) Cohort
-------------------------------------------------------------------- -----------------
Observed Patterns of Systemic Therapy Use in Hepatocellular April 20, 12:30 -
Carcinoma (HCC) Patients from the Multinational HCC BRIDGE Study: 2:00 p.m.
Results of a Second Interim Analysis
-------------------------------------------------------------------- ----------------- |
发表于 2012-4-4 20:26
